Friday, June 01, 2018 10:26:33 AM
https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded?mkt_tok=eyJpIjoiWkdZNFpHUTJZMlE1WmpkaCIsInQiOiJZTGNBT0xCcmtWZVpWVFhEY0wrbnYxc3M1eHdJcTNETXpkOUxcLytkU0dsQ0JWbEZOblhQSWhQYmhMWHRscEhYcU9HR0xsMzBiaHkxOEVUaUo1anVFRzRicjYxQUJEa21zRlJvRHlrRk5md0l6OGU0a0xoVlF3MFY5c3ptZGR5c1MifQ%3D%3D&mrkid=41425082
The question is, how soon will Maviret be approved for China?
Per the article; "Gilead then won approval for Sovaldi in September, the same time AbbVie got its ombitasvir and dasabuvir combo through."
(It's possible this is correct, but I keep thinking that sovaldi is a single drug which FDA approval preceeded the Abbvie 3D program by a year- article suggests 3D program was china approved before Harvoni, and then went straight to Epclusa approval-hmmmmm?!? ~W)
In any case, Epclusa approval (june 2016) preceded Mavyret US approval by over a year. It will be interesting to see how quickly Mavyret gains use in China.
FWIW, the 3D first gen Abbvie program was very effective in the Japanese market and China is comparable in both genetic makeup and in genotype pool. China could be a good market, and if the approval labeling were to be comparable to US and ex-US, it could offer the shortest pan-genotypic cure available to China's 10 million HCV+.
There are 7 more months left in the year. How soon will Maviret be approved in China?
Recent ENTA News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 12:38:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:15:05 PM
- Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:37:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:00:34 PM
- Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference • Business Wire • 05/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:14 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 05/06/2024 08:01:00 PM
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 11:10:00 AM
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer • Business Wire • 04/30/2024 11:00:00 AM
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 • Business Wire • 04/29/2024 11:00:00 AM
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
- Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference • Business Wire • 03/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:31:52 PM
- Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/27/2024 06:11:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:23:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:21:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:18:12 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM